What is the difference between MK-677 and CJC-1295?

MK-677 (ibutamoren) is an oral, non-peptide small molecule that mimics ghrelin at the GHS-R1a receptor and produces a sustained, roughly 24-hour rise in GH and IGF-1 from a single daily dose. CJC-1295 is an injectable GHRH analog that works on a different receptor (the GHRH receptor) and, paired with ipamorelin, drives discrete pulsatile GH release through two pathways. The headline differences are route (oral vs injection) and kinetics (flat continuous elevation vs physiological pulses). This is a research reference, not medical advice.

No. MK-677 is a non-peptide growth-hormone secretagogue — a small organic molecule (ibutamoren mesylate), not a chain of amino acids. It gets grouped with peptides like ipamorelin and CJC-1295 because it acts on the same GH axis and is studied for the same goals, but the chemistry is different. That distinction also changes verification: MK-677's identity is confirmed like a small-molecule drug, whereas CJC-1295 and ipamorelin are confirmed by peptide sequence.

Which produces more physiological growth hormone release?

In terms of matching the body's own pattern, the injectable GHRH-analog approach (CJC-1295 with ipamorelin) produces discrete GH pulses that more closely resemble natural pulsatile secretion, whereas MK-677's long half-life produces a flatter, sustained 24-hour elevation. Neither is universally 'better' — a researcher chooses based on whether the model calls for pulse fidelity or continuous elevation. Nothing here is an efficacy claim or a recommendation for use in people.

Why is MK-677 compared to a CJC-1295 blend instead of CJC-1295 alone?

In practice CJC-1295 is almost always studied alongside a selective secretagogue such as ipamorelin, because combining a GHRH-receptor signal with a ghrelin-receptor signal amplifies GH pulses through two separate pathways. Titan stocks exactly that combination as a CJC-1295 + Ipamorelin blend. Comparing MK-677 to the blend reflects how the injectable approach is actually used, rather than an isolated single agent. For the single-peptide head-to-head, see MK-677 vs ipamorelin.

Does Titan sell both MK-677 and CJC-1295?

Titan stocks the CJC-1295 + Ipamorelin injectable blend as a research-use-only reagent ($119.99). Titan does not stock MK-677 — it is discussed on this page only as the oral comparator. Everything here summarises published pharmacology as a research reference for in-vitro laboratory work, not for human or animal consumption, and is not medical or dosing advice.

MK-677 vs CJC-1295 · GH-axis comparison · research use only

MK-677 vs CJC-1295: an oral molecule that raises GH all day vs an injectable that restores the pulse.

MK-677 and CJC-1295 are grouped together because both raise growth hormone (GH) and IGF-1 in research models — but they do it through different receptors, by different routes, and with opposite kinetics, which is the whole reason a researcher would choose between them. MK-677 (ibutamoren) is a non-peptide small molecule taken orally; it mimics ghrelin at the growth-hormone-secretagogue receptor (GHS-R1a) and, because it is orally bioavailable and long-acting, a single daily dose produces a sustained elevation of GH and IGF-1 across roughly 24 hours — a flat, continuous rise. CJC-1295 is a growth-hormone-releasing-hormone (GHRH) analog delivered by subcutaneous injection; it works on the GHRH receptor, a separate arm of the same axis, and in research it is usually paired with a selective secretagogue such as ipamorelin so the two pathways (GHRH + ghrelin-receptor) amplify discrete, physiological GH pulses rather than a flat elevation. So the core contrast is sustained-oral-elevation versus pulsatile-injectable-release. There is also a chemistry distinction that matters for verification: MK-677 is not a peptide at all — it is a small organic molecule, so its identity is confirmed like a small-molecule drug, whereas CJC-1295 (and the ipamorelin it is blended with) are peptides confirmed by sequence. This page reproduces that published pharmacology as a research reference; it is not medical, dosing or efficacy advice.

CJC-1295 + Ipamorelin — $119.99 MK-677 vs Ipamorelin

MK-677 (ibutamoren): oral, non-peptide, ghrelin-mimetic

MK-677 binds GHS-R1a — the ghrelin (growth-hormone-secretagogue) receptor — in the pituitary and hypothalamus, mimicking ghrelin's signal to release GH, which in turn raises IGF-1. Its defining practical feature is the oral route: it avoids injection entirely. It is also long-acting, so one daily dose keeps GH and IGF-1 elevated around the clock. The same ghrelin-receptor activity that drives GH release also drives the well-documented appetite increase.

MK-677 dosage reference →

CJC-1295: injectable GHRH analog, usually run with ipamorelin

CJC-1295 is a modified GHRH analog given subcutaneously; it acts on the GHRH receptor — a different arm of the GH axis than the ghrelin receptor. In research it is typically paired with ipamorelin, a selective GHS-R1a peptide, so the GHRH signal and the ghrelin-receptor signal combine to amplify natural GH pulses through two pathways. Titan stocks this as a CJC-1295 + Ipamorelin blend. The trade-off vs MK-677 is the injection, in exchange for pulsatile rather than flat release.

CJC-1295 + Ipamorelin (in stock) →

The real dividing line: flat 24-hour elevation vs discrete pulses

This is the distinction that actually separates them. MK-677's long half-life produces a sustained, relatively flat GH/IGF-1 elevation across the day. Injectable secretagogues like CJC-1295/ipamorelin produce discrete, short-duration GH pulses that more closely resemble the body's own pulsatile secretion pattern. Neither is 'stronger' in the abstract — a researcher picks based on whether the model calls for continuous elevation or pulse fidelity.

How the blend's kinetics work →

Secondary effects: MK-677's appetite and glucose signal

Because MK-677 activates the ghrelin receptor, its documented profile includes increased appetite and effects on glucose handling (a rise in fasting glucose with reduced insulin sensitivity has been reported in longer studies). Ipamorelin, by contrast, is prized in research for its selectivity — it releases GH without the cortisol, prolactin or GHRP-6-style hunger seen with less selective secretagogues. That selectivity vs sustained-ghrelin-tone difference is often the deciding factor.

MK-677 side-effect record →

Verification: small-molecule QC vs peptide-sequence COA

The chemistry gap changes what a certificate of analysis must prove. MK-677 is a non-peptide small molecule (ibutamoren mesylate) sold as a salt — its identity is confirmed by small-molecule methods (HPLC/MS for the molecule and its counterion), not a sequence. CJC-1295 and ipamorelin are peptides — a blend COA has to confirm both sequences by mass and identify each component, because a purity number alone can't prove a two-peptide blend is correct. Different molecules, different documentation.

How Titan documents identity →

Research-use framing and what Titan stocks

Everything here summarises published pharmacology reproduced as a research reference for laboratory and in-vitro modelling — not instructions for human use, and not a claim that either compound is superior or effective in people. Titan stocks the CJC-1295 + Ipamorelin injectable blend as a research-use-only reagent; Titan does not stock MK-677, which is discussed here only as the oral comparator. Nothing on this page is medical or dosing advice.

Lab testing & COA workflow →

The detail, in plain terms

MK-677 vs CJC-1295, side by side.

A plain-terms comparison of the two GH-axis approaches on the axes that actually differ — chemistry, route, receptor, kinetics and verification. Reproduced from published pharmacology as a research reference, not a recommendation or an efficacy claim. Titan stocks the CJC-1295 + Ipamorelin blend; MK-677 is the comparator only.

Chemical class: MK-677: non-peptide small molecule (ibutamoren). CJC-1295: peptide (GHRH analog), blended with the peptide ipamorelin.
Route: MK-677: oral, no injection. CJC-1295 / ipamorelin blend: subcutaneous injection.
Receptor target: MK-677: ghrelin receptor (GHS-R1a). CJC-1295: GHRH receptor — a separate arm of the GH axis (ipamorelin adds GHS-R1a).
Kinetics: MK-677: long-acting → sustained, flat 24-hour GH/IGF-1 elevation from one daily dose. CJC-1295/ipamorelin: discrete pulsatile GH release.
Secondary profile: MK-677: appetite increase + reported glucose/insulin-sensitivity signal. Ipamorelin: selective — GH release without cortisol/prolactin/hunger.
Verification (COA): MK-677: small-molecule identity + counterion. CJC-1295/ipamorelin: two-sequence blend COA confirming both peptides by mass.
Titan catalog: In stock: CJC-1295 + Ipamorelin blend ($119.99), research-use-only. MK-677: not stocked (comparator only).

Questions researchers ask

Before you order.

What is the difference between MK-677 and CJC-1295?: MK-677 (ibutamoren) is an oral, non-peptide small molecule that mimics ghrelin at the GHS-R1a receptor and produces a sustained, roughly 24-hour rise in GH and IGF-1 from a single daily dose. CJC-1295 is an injectable GHRH analog that works on a different receptor (the GHRH receptor) and, paired with ipamorelin, drives discrete pulsatile GH release through two pathways. The headline differences are route (oral vs injection) and kinetics (flat continuous elevation vs physiological pulses). This is a research reference, not medical advice.
Is MK-677 a peptide?: No. MK-677 is a non-peptide growth-hormone secretagogue — a small organic molecule (ibutamoren mesylate), not a chain of amino acids. It gets grouped with peptides like ipamorelin and CJC-1295 because it acts on the same GH axis and is studied for the same goals, but the chemistry is different. That distinction also changes verification: MK-677's identity is confirmed like a small-molecule drug, whereas CJC-1295 and ipamorelin are confirmed by peptide sequence.
Which produces more physiological growth hormone release?: In terms of matching the body's own pattern, the injectable GHRH-analog approach (CJC-1295 with ipamorelin) produces discrete GH pulses that more closely resemble natural pulsatile secretion, whereas MK-677's long half-life produces a flatter, sustained 24-hour elevation. Neither is universally 'better' — a researcher chooses based on whether the model calls for pulse fidelity or continuous elevation. Nothing here is an efficacy claim or a recommendation for use in people.
Why is MK-677 compared to a CJC-1295 blend instead of CJC-1295 alone?: In practice CJC-1295 is almost always studied alongside a selective secretagogue such as ipamorelin, because combining a GHRH-receptor signal with a ghrelin-receptor signal amplifies GH pulses through two separate pathways. Titan stocks exactly that combination as a CJC-1295 + Ipamorelin blend. Comparing MK-677 to the blend reflects how the injectable approach is actually used, rather than an isolated single agent. For the single-peptide head-to-head, see MK-677 vs ipamorelin.
Does Titan sell both MK-677 and CJC-1295?: Titan stocks the CJC-1295 + Ipamorelin injectable blend as a research-use-only reagent ($119.99). Titan does not stock MK-677 — it is discussed on this page only as the oral comparator. Everything here summarises published pharmacology as a research reference for in-vitro laboratory work, not for human or animal consumption, and is not medical or dosing advice.